At Deciphera Pharmaceuticals, we are developing novel drug candidates to improve the lives of cancer patients by addressing key mechanisms of drug resistance that limit the effectiveness of many cancer therapies.
Our pipeline of drug candidates has been designed using our proprietary kinase switch control inhibitor platform. Kinases are an important family of enzymes, that when mutated or over expressed are known to be directly involved in the growth and spread of many cancers.
We have built a diverse pipeline of wholly owned, orally administered drug candidates that includes three clinical-stage and two research-stage programs. We designed our lead drug candidate, DCC-2618, to inhibit the full spectrum of the known mutant or amplified KIT and PDGFRα kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors.
We are also developing two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, or immunokinase, inhibitors targeting the kinases CSF1R, and TIE2 kinase, respectively.